20 April 2020
Researchers from CSIRO, Australia’s national science agency, have unveiled a new approach to analysing the genetic codes – or the blueprint – of the SARS-CoV-2 virus that causes COVID-19.
The findings will help researchers better understand how strains of the virus evolve and help identify new clusters of the virus.
Analysing global data on the published genome sequences of this novel coronavirus will help fast track our understanding of this complex disease.
The researchers developed a novel visualisation platform, underpinned by bioinformatics algorithms originally used to analyse the human genome, to pinpoint differences among the thousands of genetic sequences of the SARS-CoV-2 virus.
CSIRO Chief Executive Dr Larry Marshall said knowing the genetic code was vital.
“The more we know about this virus, the better armed we’ll be to fight it,” Dr Marshall said.
“This highly complex analysis of the genome sequence of the SARS-CoV-2 virus has already helped to determine which strains of the virus are suitable for testing vaccines underway at the Australian Centre for Disease Preparedness in Geelong – the only high biocontainment facility of its kind in the Southern Hemisphere.”
Understanding genome sequences helps researchers choose the right strain of the virus for vaccine and diagnostic efforts.
CSIRO’s Bioinformatics Team Leader Dr Denis Bauer said as the virus evolved, the blueprint becomes increasingly important, effectively because it holds instructions about the behaviour of the virus and what kind of disease it can cause.
“Globally there is now a huge amount of individual virus sequences,” Dr Bauer, who is also Honorary Associate Professor at Macquarie University, Australia said.
“Assessing the evolutionary distance between these data points and visualising it helps researchers find out about the different strains of the virus – including where they came from and how they continue to evolve.”
CSIRO’s Dangerous Pathogens Team Leader Professor S.S. Vasan, who is leading the SARS-CoV-2 virus work and vaccine evaluation studies and is the corresponding author of the paper, said the first 181 published genome sequences from the current COVID-19 outbreak were analysed to understand how changes in the virus could affect its behaviour and impact.
“This RNA virus is expected to evolve into a number of distinct clusters that share mutations, which is what we have confirmed and visualised,”Professor Vasan, who holds an honorary chair at the University of York, Uk said.
“At this time, we do not expect it will affect the development and evaluation of COVID-19 vaccines, therapies and diagnostics, but it is important information to monitor as preclinical and clinical studies progress.
“To enable this, we are calling on the international research community to share de-identified details of case severity and outcome, and other relevant meta-data such as co-morbidities and smoking status, alongside the genomic sequences of the virus.”
CSIRO’s Australian e-Health Research Centre CEO David Hansen said the work shows the importance of cross-collaboration between the established and emerging disciplines of bioinformatics, genomics, vaccinology and virology.
“Following the scientific process of peer-reviewed open publication such as this one is a vitally critical component of the CSIRO’s response,” Dr Hansen said.
“The advantage of the data visualisation platform is that it highlights evolving genetic mutations of the virus as it continues to change and adapt to new environments,” Dr Bauer said.
“The more informed we are about the genetic differences and their likely consequences on the progression of the disease, the better we can tackle the disease with diagnostics and treatments.”
The peer-reviewed research paper, Supporting pandemic response using genomics and bioinformatics: a case study on the emergent SARS-CoV-2 outbreak , was accepted for publication by the Transboundary and Emerging Diseases journal on 7 April 2020.
The COVID-19 genome visualisation platform can be found Genomic Signature analysis of SARS-CoV-2 .
Read the full media release.
